Frequently Asked Questions

Got questions? We’ve answered the most common ones below. If you don’t see your question, call us anytime.

 

The test screens for hepatocellular carcinoma (HCC) — the most common form of primary liver cancer. We analyze your blood for fusion gene biomarkers that are specific to early-stage liver cancer. These markers appear in the bloodstream significantly earlier than tumors become visible on ultrasound or CT scans.

The test requires only a standard venipuncture — the same blood draw you’d receive at any clinic or doctor’s office. It is not a biopsy. There’s no tissue removal, no surgery, and no imaging. Most people describe it as mild and brief. The certified phlebotomist comes to your home and the draw itself takes 5–10 minutes.
 
The Fusion-detect™ test achieves 96.7% overall accuracy, 94.2% sensitivity, and 98.1% specificity in clinical validation. A liver biopsy is considered definitive for diagnosis — but it is invasive, carries risks of bleeding and infection, and is not suitable as a screening tool. Our test is a screening tool that identifies patients who need further investigation. For a positive MoleculeDx result, we facilitate referral to a physician for confirmatory imaging or biopsy if warranted.
 
MoleculeDx is accepted by most major US insurers including UnitedHealth, Anthem/Blue Cross Blue Shield, Aetna, Cigna, Humana, and UPMC Health Plan. Medicare Advantage plans are also accepted. Coverage for cancer screening tests varies by plan and diagnosis code. Our team will verify your specific coverage for free before you book — contact us or check at booking.moleculedx.com.
 
Results are delivered digitally within 24 hours of sample receipt at our laboratory. You’ll receive a secure notification by email or SMS with access to your full clinical report. For results that require attention, a care coordinator will reach out to you directly within the same window to guide next steps.
 
A positive result does not mean you have cancer — it means biomarkers were detected that warrant further evaluation. Our care coordinator will contact you immediately to explain your results in plain language and help arrange follow-up imaging (typically an MRI or CT) and referral to a hepatologist or oncologist. We work with your existing providers or can refer you to UPMC specialists depending on your location.
 
Yes. Through our exclusive partnership with University of Pittsburgh Medical Center, patients can walk into any UPMC facility and request the MoleculeDx liver cancer screening test. UPMC physicians can also order it directly through UPMC’s Epic EHR system. Results are delivered within 24 hours and integrated directly into your UPMC health record.
 
We partner with Portamedic (portamedic.com) and Travalab (travalab.com) — two of the largest and most trusted mobile phlebotomy networks in the United States. All phlebotomists are nationally certified (CPT or equivalent) and undergo background checks and quality assurance training specific to MoleculeDx sample handling protocols.
 
No referral is required to book a self-pay test. However, insurance coverage typically requires an ordering physician. If you don’t have a primary care provider, our care coordinators can help connect you with a telemedicine physician who can provide the order — often within the same day.
 
At-home phlebotomy through Portamedic and Travalab is available across all 50 US states, though coverage in rural areas may require advance scheduling of 3–5 days. Walk-in testing is currently available exclusively at UPMC locations. We are actively expanding our clinical site network — check booking.moleculedx.com for your specific zip code coverage.
 

Still Have Questions?

Our patient support team is available Monday–Saturday, 8am–8pm EST. We’re here to help — no question is too small.